CD1a PerCP-Cyanine5.5
Catalog #
Size
Molt-4 gated cells stained with CD1a (OKT6) PerCP-Cyanine5.5 (RED); Molt-4 gated cells are used as FMO control (BLUE).
| Conjugation | PerCP-Cyanine5.5 |
|---|---|
| Antigen | CD1a |
| Clone | OKT6 |
| Isotype | IgG1, k |
| Applications | FC |
| Reactivity | Human |
| Host | Mouse |
| Clonality | Monoclonal |
| Primary/Secondary | Primary |
| Immunogen | Human acute lymphoblastic leukemia cells |
| Format | 0.09% sodium azide, 0.2% BSA (w/v), PBS pH 7.2 |
| Storage | 2-8°C |
| Status | RUO |
| Excitation Laser | Blue (488nm) |
Description:
The clone OKT6, a mouse monoclonal antibody selectively recognizes 49-kDa type I transmembrane glycoprotein non-covalently associated with β2-microglobulin known as CD1a. The CD1a glycoprotein has structural similarities to MHC class I molecule and plays important role in antigen-presenting mechanism to T-cell receptors present on NK T-cells. It is expressed on cortical double positive and single positive thymocytes, Langerhans cells, and dendritic cells. In addition to antigen presentation NK T-cells, CD1a has been implicated in thymic T cell development. CD1a has been used as a marker for DCs in a range of human tumors and the density of CD1a DC has been associated with clinical outcome in patients with lung, colon, gastric, nasopharyngeal, laryngeal and tongue carcinomas.
The clone OKT6, a mouse monoclonal antibody selectively recognizes 49-kDa type I transmembrane glycoprotein non-covalently associated with β2-microglobulin known as CD1a. The CD1a glycoprotein has structural similarities to MHC class I molecule and plays important role in antigen-presenting mechanism to T-cell receptors present on NK T-cells. It is expressed on cortical double positive and single positive thymocytes, Langerhans cells, and dendritic cells. In addition to antigen presentation NK T-cells, CD1a has been implicated in thymic T cell development. CD1a has been used as a marker for DCs in a range of human tumors and the density of CD1a DC has been associated with clinical outcome in patients with lung, colon, gastric, nasopharyngeal, laryngeal and tongue carcinomas.